(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 October 2014 (02.10.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/160129 A2

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2014/025882

(22) International Filing Date:
13 March 2014 (13.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/782,531	14 March 2013 (14.03.2013)	US
61/837,399	20 June 2013 (20.06.2013)	US
61/904,579	15 November 2013 (15.11.2013)	US
61/912,777	6 December 2013 (06.12.2013)	US
61/942,367	20 February 2014 (20.02.2014)	US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(72) Inventors: **FITZGERALD, Kevin**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **BUTLER, James**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **BETTENCOURT, Brian**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **BORODOVSKY, Anna**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **KUCHIMANCHI, Satyanarayana**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **CHARISSE, Klaus**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **MANOHARAN, Muthiah**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **MAIER, Martin**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **RAJEEV, Kallanthottathil, G.**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **FOSTER, Donald**; 300 Third Street, Cambridge, MA 02142 (US).

(74) Agents: **ZACHARAKIS, Maria, Laccotripe** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF




Figure 1

(57) Abstract: The invention relates to iRNA, *e.g.*, double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, *e.g.*, dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, *e.g.*, paroxysmal nocturnal hemoglobinuria.

WO 2014/160129 A2

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*